David R Epstein
CIK 1445826 · CEO · last filed 2026-10-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SGEN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
DELRAY BEACH, FL 33483
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AGMB | Director | 15,000 | $8.23 | $123.5K | $130.8K | 2 | 2026-10-09 |
| TEM | Director | 30,844 | $64.34 | $1.98M | -$310.4K | 18 | 2026-09-03 |
| Seagen Inc. (SGEN) Delisted | CEO | 0 | $228.74 | $0 | -$2.26M | 4 | 2023-12-15 |
| SNTI | Director | — | $0.23 | — | $0 | 1 | 2022-07-15 |
| Evelo Biosciences, Inc. (EVLO) Delisted | Director | 4,697 | $0.00 | $0 | $120.7K | 19 | 2022-06-30 |
| Axcella Health Inc. (AXLA) Delisted | Director | 8,390 | $0.40 | $3.4K | $786.7K | 29 | 2022-06-03 |
| Rubius Therapeutics, Inc. (RUBY) Delisted | Director | 4,720,012 | $0.08 | $391.8K | -$1.77M | 10 | 2022-05-13 |
| INTERNATIONAL FLAVORS & FRAGRANCES INC (IFFT) Delisted | Director | — | $47.56 | — | $0 | 5 | 2020-11-04 |
| IFF | Director | — | $90.96 | — | $0 | 9 | 2018-05-03 |
| Molecular Insight Pharmaceuticals, Inc. (MIPI) Delisted | Director | — | — | — | $0 | 1 | 2008-09-24 |
Recent Filings · Page 4 of 11
107 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-08-17 | Seagen Inc. (SGEN) Delisted | Grant (A) | +39,650 | $0 | EDGAR |
| 2022-11-14 | Seagen Inc. (SGEN) Delisted | Grant (A) | +107,389 | $0 | EDGAR |
| 2022-07-15 | SNTI | Grant (A) | — | $0 | EDGAR |
| 2022-06-30 | Evelo Biosciences, Inc. (EVLO) Delisted | Exer (M) | +4,927 | $0 | EDGAR |
| 2022-06-13 | Evelo Biosciences, Inc. (EVLO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-10 | — | Mixed | +112,519 | $0 | |
| 2022-06-03 | Axcella Health Inc. (AXLA) Delisted | Grant (A) | +47,059 | $0 | EDGAR |
| 2022-06-01 | Evelo Biosciences, Inc. (EVLO) Delisted | Exer (M) | +4,925 | $0 | EDGAR |
| 2022-05-31 | Evelo Biosciences, Inc. (EVLO) Delisted | Buy (P) | +17,123 | $25.0K | EDGAR |
| 2022-05-13 | Rubius Therapeutics, Inc. (RUBY) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.